GlassScriptPhysician profile
Geena Sethi
NPI 1811418841
$3,228.44
in general payments reported to CMS, 2019-2025
23 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $827 · 2023: $485 · 2024: $1,189 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.56 | 2023-2025 | Vraylar |
| Alkermes, INC. | $683.80 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $245.69 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.62 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $228.52 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $187.11 | 2021-2024 | Trintellix |
| Lundbeck LLC | $175.65 | 2022-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $158.50 | 2021-2024 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $57.54 | 2022-2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $49.66 | 2023 | Givlaari |
| Neurocrine Biosciences, INC. | $37.15 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.06 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $30.22 | 2024 | Relexxii |
| Axsome Therapeutics, INC. | $29.57 | 2024 | Auvelity |
| Almatica Pharma LLC | $26.54 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $19.78 | 2024 | Xelstrym |
| Biogen, INC. | $18.32 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $17.89 | 2022 | |
| Livanova USA, INC. | $16.21 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Exact Sciences Corporation | $15.00 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.59 | 2023 | Xifaxan, Trulance |
| Brainsway USA INC | $13.59 | 2023 | |
| Bausch Health US, LLC | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geena Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.